Skip to main content
Clinical Trials/ISRCTN62225263
ISRCTN62225263
Completed
未知

A prospective investigation of the feasibility of smartphone-based self-monitoring to characterize cognitive and neurological impairment in patients with multiple sclerosis (Floodlight MS_More Active)

F. Hoffmann-La Roche Ltd0 sites279 target enrollmentMarch 11, 2022

Overview

Phase
未知
Intervention
Not specified
Conditions
Multiple sclerosis
Sponsor
F. Hoffmann-La Roche Ltd
Enrollment
279
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 11, 2022
End Date
July 31, 2024
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Current participant inclusion criteria as of 21/12/2023:
  • 1\. Be able to provide informed consent to the study, and to participate in the MSBase registry and the MRI repository
  • 2\. Aged 18 years or older
  • 3\. EDSS in the range of 1\.0 to 7\.0 inclusive
  • 4\. Diagnosis of MS (new or revised) based on the 2017 revised McDonald criteria
  • 5\. Untreated or treated with an approved or off\-label DMT, if DMT was initiated \>3 months ago
  • 6\. Must have a personal smartphone
  • 7\. Willing to discontinue participation in any other Floodlight application.
  • Previous participant inclusion criteria:
  • 1\. Be able to provide informed consent to the study, and to participate in the MSBase registry and the MRI repository

Exclusion Criteria

  • 1\. Unable to provide data to establish a minimum dataset
  • 2\. Any contraindication for use of smartphone as per the investigator’s discretion
  • 3\. Known significant cognitive impairment as per the investigator’s discretion
  • 4\. Not able to tolerate routine clinical MRI
  • 5\. Clinical relapse in the 30 days before enrolment.

Outcomes

Primary Outcomes

Not specified

Similar Trials